Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors

OBJECTIVES: Although many newer diabetes medications have become available in the last decade, most have not been widely studied in populations with chronic kidney disease under routine care. Linagliptin, a recently marketed dipeptidyl peptidase 4 (DPP‐4) inhibitor, is the only agent in the U.S. tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Patorno, Elisabetta, Gopalakrishnan, Chandrasekar, Bartels, Dorothee B., Brodovicz, Kimberly G., Liu, Jun, Schneeweiss, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360917/
https://www.ncbi.nlm.nih.gov/pubmed/30815542
http://dx.doi.org/10.1002/edm2.5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360917/
https://www.ncbi.nlm.nih.gov/pubmed/30815542
http://dx.doi.org/10.1002/edm2.5

Ejemplares similares